Glutamic acid

Global Glutamic Acid Market Size, Share & Trends Analysis Report 2021-2028: Increasing Demand for Glutamic Acid in Pharmaceutical Products & Supplements - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 14, 2021
Chemicals, Plastics, Manufacturing, Chronic Respiratory Disease, Food, Glutamic acid, Health, Cosmetics, Muscular dystrophy, Epilepsy, Population, Drink, Growth, Degenerative disease, Dietary supplement, Industry, MEA, COVID-19, Cancer, Adoption, Animal feed, Evonik Industries, CAGR, Livestock, Ageing, CSA, Fine chemical, Agriculture

Strong demand for the product in the animal feed and food and beverage industries has increased the price of glutamic acid.

Key Points: 
  • Strong demand for the product in the animal feed and food and beverage industries has increased the price of glutamic acid.
  • Moreover, disturbance caused by the COVID-19 pandemic in the raw material supply chain is another factor behind the increasing prices of glutamic acid.
  • Manufacturers compete based on distribution channels and strive to expand their market reach to increase their market share and bolster the annual revenue.
  • Glutamic acid manufacturers focus on improving their products and enhancing their manufacturing capabilities to distinguish their products from the products of other manufacturers in the industry and enhance their market share.

Addex to Present at the Virtual German Equity Forum

Retrieved on: 
Thursday, November 18, 2021
Dyskinesia, SIX Swiss Exchange, Discovery, CEO, Glutamic acid, Protein, American depositary receipt, Allosteric regulation, Glutamate receptor, Glutamate (neurotransmitter), Neurodegeneration, PTSD, ADX71149, Clinical trial, Biology, Blepharospasm, Dystonia, NAM, EST, Nasdaq, Janssen Pharmaceuticals, PAM, L-DOPA, GABAB, Therapy, Lists of diseases, Epilepsy, Drug discovery, Pharmaceutical industry

Geneva, Switzerland, November 18, 2021- Addex Therapeutics (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, and Head of Discovery Biology, Dr Robert Ltjens, will be attending the virtual German Equity Forum to be held November 22 24, 2021.

Key Points: 
  • Geneva, Switzerland, November 18, 2021- Addex Therapeutics (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, and Head of Discovery Biology, Dr Robert Ltjens, will be attending the virtual German Equity Forum to be held November 22 24, 2021.
  • In his presentation, Mr Dyer will provide a corporate update and discuss recent developments at Addex.
  • Management will be available for virtual one-on-one meetings throughout the conference.
  • Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention.

Addex Strategic Partner Successfully Completes Phase 1 in Japan with ADX71149

Retrieved on: 
Monday, November 15, 2021
Seizure, Dyskinesia, Safety, Glutamate (neurotransmitter), PTSD, Glutamic acid, Blepharospasm, Therapy, ADX71149, SIX Swiss Exchange, Clinical trial, Dystonia, Neurodegeneration, GABAB, Levetiracetam, L-DOPA, Lists of diseases, PAM, American depositary receipt, Janssen Pharmaceuticals, Allosteric regulation, NAM, Metcalf, Nasdaq, Protein, LR, Johnson & Johnson, Drug discovery, Pharmacokinetics, Patient, Glutamate receptor, Brain, Pharmaceutical industry

The successful completion of this Phase 1 safety program will enable centers in Japan to be included in a potential global development of ADX71149 for the treatment of epilepsy.

Key Points: 
  • The successful completion of this Phase 1 safety program will enable centers in Japan to be included in a potential global development of ADX71149 for the treatment of epilepsy.
  • ADX71149 is currently in a transatlantic Phase 2 epilepsy study.
  • The successful completion of safety studies is important so that Japan can be included in a potential global development program of ADX71149 for the treatment of epilepsy, said Tim Dyer CEO of Addex.
  • The ongoing study of ADX71149 in epilepsy patients is on track to deliver interim results in Q3 2022, which will guide future development.

Addex to Present at the H.C. Wainwright 7th Annual Israel Virtual Conference

Retrieved on: 
Monday, November 15, 2021
Dyskinesia, Glutamate (neurotransmitter), PTSD, Blepharospasm, Therapy, ADX71149, SIX Swiss Exchange, Epilepsy, Clinical trial, Dystonia, CEO, Neurodegeneration, EST, GABAB, Glutamic acid, L-DOPA, Lists of diseases, PAM, American depositary receipt, Nasdaq, Allosteric regulation, NAM, Protein, Conference, Janssen Pharmaceuticals, Drug discovery, Glutamate receptor, Pharmaceutical industry

Geneva, Switzerland, November 15, 2021- Addex Therapeutics (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present at the H.C. Wainwright 7th Annual Israel Virtual Conference .

Key Points: 
  • Geneva, Switzerland, November 15, 2021- Addex Therapeutics (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present at the H.C. Wainwright 7th Annual Israel Virtual Conference .
  • In his presentation, which is scheduled for today, November 15, 2021 at 08:30 EST / 14:30 CET, Mr Dyer will provide a corporate update and discuss recent developments at Addex.
  • Management will be available for virtual one-on-one meetings throughout the conference.
  • For more information or to schedule a one-on-one meeting with management, please contact your conference representative or [email protected] .

Addex Reports Q3 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, November 4, 2021
Research, SIX Swiss Exchange, Neurodegeneration, Glutamate (neurotransmitter), Dystonia, American depositary receipt, Drug discovery, PTSD, Consultant, Review, PAM, GABAB, CHF, NAM, Dyskinesia, Protein, Patent, Financial statement, Clinical trial, ADS, Glutamic acid, Depreciation, Nasdaq, EDT, Allosteric regulation, Lists of diseases, R, G&A, Janssen Pharmaceuticals, Q&A, Therapy, Blepharospasm, Epilepsy, ATM, Sale, Glutamate receptor, ADX71149, L-DOPA, Lithium, Pharmaceutical industry

During the nine-month period ended September 30, 2021, income increased by CHF 0.8 million to CHF 2.8 million compared to the nine-month period ended September 30, 2020.

Key Points: 
  • During the nine-month period ended September 30, 2021, income increased by CHF 0.8 million to CHF 2.8 million compared to the nine-month period ended September 30, 2020.
  • During the third quarter of 2021, income increased by CHF 0.7 million compared to CHF 0.8 million in the third quarter of 2020.
  • During the same period staff costs increased by CHF 0.3 million, primarily due to increased R&D headcount.
  • 2021 Q3 Condensed Consolidated Interim Financial Statements:
    A conference call will be held today,November 4, 2021, at 16:00 CET (15:00 GMT / 11:00 EDT / 08:00 PDT) to review the financial results.

Addex Therapeutics to Release Q3 2021 Financial Results and Host Conference Call on November 4, 2021

Retrieved on: 
Monday, November 1, 2021
SIX Swiss Exchange, Neurodegeneration, Glutamate (neurotransmitter), Dystonia, American depositary receipt, Drug discovery, PTSD, Review, PAM, GABAB, Dyskinesia, NAM, Protein, Nasdaq, Clinical trial, Webcast, CEO, Glutamic acid, EDT, Allosteric regulation, Lists of diseases, Therapy, Janssen Pharmaceuticals, Blepharospasm, Epilepsy, CMO, Glutamate receptor, ADX71149, L-DOPA, Pharmaceutical industry

Geneva, Switzerland, November 1, 2021 Addex Therapeutics (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that it will issue its Q3 2021 financial results on Thursday, November 4, 2021.

Key Points: 
  • Geneva, Switzerland, November 1, 2021 Addex Therapeutics (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that it will issue its Q3 2021 financial results on Thursday, November 4, 2021.
  • 1: In the 10 minutes prior to the call start time, call the appropriate participant dial-in number.
  • Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention.
  • Indivior PLC has licensed Addexs GABAB PAM program for the development of drug candidates with a focus in addiction.

Addex to Present at the Investors’ Day hosted by Voxia Communication

Retrieved on: 
Wednesday, October 6, 2021
Therapy, Clinical trial, CEST, Neurodegeneration, Janssen Pharmaceuticals, Epilepsy, PAM, Dyskinesia, SIX Swiss Exchange, Nasdaq, Glutamate (neurotransmitter), American depositary receipt, Communication, Allosteric regulation, CEO, NAM, Glutamic acid, Dystonia, Blepharospasm, ADX71149, Drug discovery, PTSD, Glutamate receptor, GABAB, Beau Rivage, Protein, Lists of diseases, L-DOPA, Pharmaceutical industry, Security (finance)

Geneva, Switzerland, October 6, 2021- Addex Therapeutics (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present at the Investors Day hosted by V oxia C ommunication (October 7, 2021).

Key Points: 
  • Geneva, Switzerland, October 6, 2021- Addex Therapeutics (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present at the Investors Day hosted by V oxia C ommunication (October 7, 2021).
  • In his presentation, which is scheduled for Thursday, October 7, 2021, at 12:10 CEST, Mr Dyer will provide a corporate update and discuss recent developments at Addex.
  • Investors Day is an event created and hosted by the Geneva and Zurich based communication agency Voxia Communication.
  • Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention.

New Cellular Health Publication Highlights Potential Benefits of GlyNAC Supplementation as a Novel Nutritional Approach to Healthy Aging

Retrieved on: 
Monday, October 4, 2021
Mitochondrion, Dementia, Respiration (physiology), Review, Cysteine, Glutathione, Research, Oxidative stress, Solution, Degenerative disease, Ageing, Health, Multimedia, Chemistry (relationship), Cellular senescence, Population, Baylor College of Medicine, MD, Body composition, Diabetes, Medicine, Glutamic acid, American Society for Nutrition, Journal of Nutrition, Antioxidant, Hepatotoxicity, Science, Journal, Human, Cell, Kidney, Baylor University, Muscle, Organic acid, Society, Metabolism, Dietary supplement, Sulfur, Mobile phone

Aging is associated with increases in free radicals which result in increasing oxidative stress and potentially cellular damage.

Key Points: 
  • Aging is associated with increases in free radicals which result in increasing oxidative stress and potentially cellular damage.
  • Evidence to date suggests that addressing cellular health concerns with nutritional interventions may help to promote healthy aging and could revolutionize how we counteract common declines associated with aging.
  • Data available on GlyNAC supplementation ranging from 2-24 weeks show that it is considered a well-tolerated, physiological approach to promoting healthy glutathione levels and supporting many cellular facets of aging.
  • Led by these research breakthroughs in cellular nutrition, Nestle Health Science has introduced Celltrient Cellular Nutrition, a specialized range of nutritional solutions designed to support cellular health.

Addex to Present at the 10th International Meeting on Metabotropic Glutamate Receptors

Retrieved on: 
Monday, October 4, 2021
Therapy, Clinical trial, Neurodegeneration, Janssen Pharmaceuticals, Epilepsy, Discovery, Metabotropic glutamate receptor 3, Biology, PAM, Dyskinesia, International Meeting for Autism Research, SIX Swiss Exchange, Private Securities Litigation Reform Act, Nasdaq, Glutamate (neurotransmitter), American depositary receipt, Allosteric regulation, NAM, Dystonia, Glutamic acid, Blepharospasm, ADX71149, Post-traumatic stress disorder, Chemistry, Drug discovery, PTSD, Glutamate receptor, GABAB, SEC, Protein, Lists of diseases, L-DOPA, Risk management, Pharmaceutical industry

Addex Therapeutics explicitly disclaims any obligation to update any forward-looking statements.

Key Points: 
  • Addex Therapeutics explicitly disclaims any obligation to update any forward-looking statements.
  • Geneva, Switzerland, October 4, 2021- Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that Dr Robert Ltjens, Head of Discovery Biology and Dr Jean-Philippe Rocher, Head of Discovery Chemistry, will present at the 10th International Meeting on Metabotropic Glutamate Receptors (October 1 - 6, 2021).
  • For more information or to schedule a one-on-one meeting with management, please contact us at [email protected] .
  • Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention.

Addex to Present at the Cantor Global Healthcare 2021 Conference

Retrieved on: 
Wednesday, September 29, 2021
EDT, Therapy, Clinical trial, CEST, Neurodegeneration, Janssen Pharmaceuticals, Epilepsy, PAM, Dyskinesia, SIX Swiss Exchange, Conference, Nasdaq, Glutamate (neurotransmitter), American depositary receipt, Allosteric regulation, CEO, NAM, Glutamic acid, Blepharospasm, ADX71149, Drug discovery, PTSD, Glutamate receptor, GABAB, Protein, Lists of diseases, L-DOPA, Pharmaceutical industry

Geneva, Switzerland, September 29, 2021- Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present at the Cantor Global Healthcare 2021 Conference (September 27 - 30, 2021).

Key Points: 
  • Geneva, Switzerland, September 29, 2021- Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present at the Cantor Global Healthcare 2021 Conference (September 27 - 30, 2021).
  • In his presentation, which is scheduled for Wednesday, September 29, 2021 at 08:00 EDT / 14:00 CEST, Mr Dyer will provide a corporate update and discuss recent developments at Addex.
  • For more information or to schedule a one-on-one meeting with management, please contact your conference representative or [email protected] .
  • Addex is also investigating dipraglurant's therapeutic use in blepharospasm (a type of dystonia), for which a clinical trial is expected to be initiated in Q3 2021.